Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CMPX
CMPX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CMPX News
Compass Therapeutics Announces Upcoming Investor Events in June
2d ago
Newsfilter
Compass Therapeutics Reports Promising Phase 1 Results for CTX-8371
4d ago
NASDAQ.COM
Compass Therapeutics Under Investigation as Stock Plummets 64.41%
May 21 2026
PRnewswire
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
May 19 2026
Globenewswire
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
May 15 2026
PRnewswire
Compass Therapeutics Announces May Investor Events Participation
May 12 2026
Newsfilter
Compass Therapeutics Reports Q1 Results with Cash Runway Until 2028
May 05 2026
seekingalpha
Tovecimig Shows Significant Survival Benefit in Biliary Tract Cancer Trial
May 05 2026
Newsfilter
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
Apr 30 2026
PRnewswire
Latest Developments in the Biotech Sector
Apr 30 2026
NASDAQ.COM
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
Apr 28 2026
Yahoo Finance
Compass Therapeutics Shares Plunge 66% After Clinical Trial Setback
Apr 27 2026
seekingalpha
High Options Volume for Compass Therapeutics and CVR Energy
Apr 27 2026
NASDAQ.COM
Compass Therapeutics Faces Investor Claims Investigation
Apr 27 2026
Globenewswire
Tovecimig Plus Paclitaxel Shows Significant Survival Benefit in BTC Study
Apr 27 2026
Newsfilter
Compass Therapeutics Reports on Tovecimig Clinical Trial Progress
Apr 27 2026
stocktwits
Show More News
